Stocks · News reference
Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2 earnings report
Read original at benzingaChardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.
Read original at benzingaGuggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and lowers the price target from $40 to $4.
Read original at benzingaEvercore ISI Group analyst Gavin Clark-Gartner downgrades Tenax Therapeutics (NASDAQ:TENX) from Outperform to In-Line and lowers the price target from $39 to $5.
Read original at benzinga